Intellia Therapeutics, Inc. (NTLA)
Last updated: 2026-10-20 16:19:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Summary
Intellia Therapeutics, Inc. (NTLA) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $11.78, with a market capitalization of $1.60B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.95 to $28.25. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.60B | |
$11.46 | |
$202.73 | |
$5.90 | |
$11.58 | |
1.19M | |
4.36M | |
-- | |
$28.25 | |
$7.95 | |
-- | |
-- |
Intellia Therapeutics, Inc. (NTLA) Stock Price Today
Intellia Therapeutics, Inc. (NTLA) is currently trading at $11.78 as of 2026-10-20 16:17:00, up 1.73% ($0.20) from the previous close of $11.58
During today's regular trading session, NTLA has traded between $5.90 and $202.73, with a trading volume of 1.19M shares. The current price is near the lower end of today's range.
Intellia Therapeutics, Inc. (NTLA) 7-Day Stock Price Change
Over the past seven days, Intellia Therapeutics, Inc. (NTLA) moved from $13.07 to $11.78, representing a decline of 9.87% ($1.29).
The stock traded between $10.91 and $13.27 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 5.92 million shares, down versus the previous seven-day period, indicating lower trading activity.
NTLA 52-Week Price Position
Position in Range: 18.9%
NTLA is currently trading at $11.78, placing it 18.9% of the way from its 52-week low of $7.95 to its 52-week high of $28.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Intellia Therapeutics, Inc. (NTLA)?
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Intellia Therapeutics, Inc. Information
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 377 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Intellia Therapeutics, Inc. (NTLA) Stock on MEXC
Eligible investors can buy real shares of Intellia Therapeutics, Inc. (NTLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Intellia Therapeutics, Inc. (NTLA) stock price today?
2.Is NTLA stock going up or down today?
3.What is NTLA pre-market price?
4.What is NTLA after-hours price?
5.Is NTLA stock trading now?
6.Where does NTLA sit relative to its 52-week high and low?
7.What sector is Intellia Therapeutics, Inc. in?
8.What is Intellia Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is NTLA valued in terms of P/E ratio and EPS?
10.Does Intellia Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
NTLA Stock Calculator
Estimate the value between NTLA shares and USD.
NTLA Shares to USD
1.00 NTLA shares = 11.78 USD
Calculations are estimates based on the latest available price and are for reference only.


